益生菌对脓毒症患儿的长期肺保护作用及其机制
该研究纳入河南省人民医院PICU 2021年3月至2022年5月收治的100例脓毒症患儿,随机分为安慰剂组和益生菌组各50例,益生菌组在常规治疗基础上口服或鼻饲益生菌0.5 g、每日3次、共30天,另选40名健康儿童为健康对照组。随访期益生菌组IL-4、IL-10、IgE及外周血和诱导痰NKT细胞比例均低于安慰剂组,PEF%和FEV1/FVC高于安慰剂组,差异均有统计学意义(P<0.05)。两组咳嗽变异性哮喘(CVA)发生率在Kaplan-Meier分析中无显著差异。多因素线性回归显示机械通气和过敏史是诱导痰NKT细胞升高的危险因素,益生菌是其独立保护因素。
要点
- 益生菌组随访期IL-4为20.3±9.3 ng/L、IL-10为23.1±6.8 ng/L,分别低于安慰剂组的27.6±11.9 ng/L和14.4±4.4 ng/L(均P<0.05)。
- 益生菌组随访期IgE为53.0±15.6 μg/L,低于安慰剂组的64.2±16.9 μg/L(P<0.05)。
- 治疗7天后益生菌组外周血NKT细胞比例为(4.2±0.9)%,低于安慰剂组的(5.3±1.2)%(P<0.05)。
- 随访期益生菌组PEF%为(91.3±4.8)%、FEV1/FVC为(91.8±4.7)%,均高于安慰剂组的(85.8±8.6)%和(87.2±7.4)%(均P<0.05)。
- 多因素线性回归显示机械通气(β=0.584,95%CI 0.069~1.099,P=0.027)和过敏史(β=0.601,95%CI 0.011~1.192,P=0.046)是NKT细胞升高的危险因素,益生菌是独立保护因素(β=-0.984,95%CI -1.378~-0.591,P=0.001)。
适用人群与场景
- 河南省人民医院PICU 2021年3月至2022年5月收治的脓毒症患儿100例,随机分为益生菌组和安慰剂组各50例。
- 另选40名健康儿童作为健康对照组。
处置流程与药物剂量
- 益生菌组在常规治疗基础上口服或鼻饲益生菌0.5 g、每日3次、共30天;安慰剂组口服安慰剂。
研究设计与关键结果
- 研究类型为随机对照研究,纳入100例脓毒症患儿随机分为益生菌组和安慰剂组各50例,另设40名健康儿童为健康对照组。
- 安慰剂组死亡2例、失访4例;益生菌组死亡3例、失访5例。
- 治疗7天后两组炎症因子均缓慢下降,两组各参数差异无统计学意义,但益生菌组下降更明显。
- 随访期益生菌组IL-4为20.3±9.3 ng/L vs 安慰剂组27.6±11.9 ng/L,IL-10为23.1±6.8 ng/L vs 14.4±4.4 ng/L,均P<0.05;IgE为53.0±15.6 μg/L vs 64.2±16.9 μg/L,P<0.05。
- 治疗7天后益生菌组外周血NKT细胞比例为(4.2±0.9)% vs 安慰剂组(5.3±1.2)%,P<0.05。
- 随访期益生菌组外周血NKT细胞为(0.024±0.009)% vs 安慰剂组(0.029±0.008)%,诱导痰NKT细胞为(0.025±0.008)% vs(0.035±0.01)%,均P<0.05,且与健康对照组相似。
- 随访期益生菌组PEF%为(91.3±4.8)% vs 安慰剂组(85.8±8.6)%,FEV1/FVC为(91.8±4.7)% vs(87.2±7.4)%,均P<0.05。
- Kaplan-Meier曲线分析显示两组CVA发生率差异无统计学意义。
证据类型、等级与局限
- 证据类型:随机对照研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为对脓毒症患儿早期应用益生菌可促进NKT细胞和炎症因子恢复,并减轻随访期肺功能损伤,有助于改善长期预后。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To observe the effects of probiotics supplementation on the natural killer T cell (NKT cell) and inflammatory factors in children with sepsis and its protective effect on long-term lung function.
METHODS: A total of 100 children with sepsis admitted to the department of pediatric intensive care unit (PICU) of Henan Provincial People's Hospital from March 2021 to May 2022 were selected as the research objects. The children were randomly divided into placebo group and probiotic group, 50 cases in each group. In addition to the conventional treatment, the probiotic group was given oral or nasal administration of 0.5 g probiotics, three times a day for 30 days, and the placebo group received oral placebo. 40 healthy children were selected as the healthy control group. The levels of interleukins (IL-4, IL-10), interferon-γ (IFN-γ) and immunoglobulin E (IgE), percentages of NKT cell in blood and induced sputum, lung function of the two groups of children with sepsis were measured before treatment, 7 days after treatment, and during follow-up. All these data were compared with those of healthy children. Kaplan-Meier analysis was used to compare the incidence of cough varied cough (CVA) between the two septic groups. Multiple linear regression analysis was used to explore the influence of various factors on the proportion of NKT cells in induced sputum.
RESULTS: In the placebo group, 2 cases died and 4 cases were lost to follow-up. In the probiotics group, 3 cases died and 5 cases were lost to follow-up. All the inflammatory factors of two groups decreased slowly after 7 day after treatment. There was no significance in the parameters of the two groups, but the levels of probiotic group declined more evidently. During the follow-up, a further decrease of inflammatory factors in probiotic group could be found, the levels of IL-4 and IL-10 were significantly different from those in the placebo group [IL-4 (ng/L): 20.3±9.3 vs. 27.6±11.9, IL-10 (ng/L): 23.1±6.8 vs. 14.4±4.4, both P < 0.05], with a significant decrease in IgE level (μg/L: 53.0±15.6 vs. 64.2±16.9, P < 0.05]. The results of flow cytometry showed that the percentage of NKT cell in peripheral blood in two septic groups decreased gradually, and the proportion of peripheral blood NKT cells in the probiotics group was significantly lower than that in the placebo group after 7 days of treatment [(4.2±0.9)% vs. (5.3±1.2)%, P < 0.05]. In the follow-up, the level of NKT cell in peripheral blood and induced sputum in probiotic group were lower than the placebo group [peripheral blood: (0.024±0.009)% vs. (0.029±0.008)%, induced sputum: (0.025±0.008)% vs. (0.035±0.01)%, both P < 0.05], which were similar to those in the healthy control group. Meanwhile, the percentage of predicted peak expiratory (PEF%) and ratio of forced expiratory volume in one second/forced vital capacity (FEV1/FVC) of probiotic group were higher than those in the placebo group [PEF%: (91.3±4.8)% vs. (85.8±8.6)%, FEV1/FVC ratio: (91.8±4.7)% vs. (87.2±7.4)%, both P < 0.05]. Although there was no significance in the incidence of CVA between two septic groups according to the Kaplan-Meier curve analysis, multiple linear regression analysis showed mechanical ventilation and allergic history were the risk factors for the increase of NKT cells [β values were 0.584, 0.601, 95% confidence interval (95%CI) were 0.069 to 1.099, 0.011 to 1.192, P = 0.027, 0.046], and probiotics was an independent protective factor for the relieve of increase in NKT cells (β value was -0.984,95%CI was -1.378 to -0.591, P = 0.001).
CONCLUSIONS: Application of probiotics to septic children early could promote the recovery of NKT cell and inflammatory factors, and alleviate the lung function injury induced by them during follow-up, which is helpful to improve the long-term prognosis of the patients.
参考来源
- Wang Y, Song H, Du F, et al. [Long-term lung protection of probiotics in children with sepsis and its mechanism]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2023. PMID: 38149388. doi:10.3760/cma.j.cn121430-20230313-00172
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。